Roche Tasmar anti-Parkinson's therapy reduces "off" time 20%-30%, U.K. labeling states.
ROCHE TASMAR REDUCES PARKINSON's "OFF" TIME 20%-30%, U.K. labeling for the therapy states. Tasmar (tolcapone) was approved by the European Medicine Evaluation Agency Aug. 27 as an adjunct to levodopa/carbidopa treatment and has become available in Germany and the U.K., Roche announced. Tasmar is the first catechol-O-methyltransferase inhibitor to come to market and will soon be available in other European countries, the company stated.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth